Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2023 Annual General Meeting
    • 2023 Special Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR+
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 29, 2023 8:00am EDT

Lexaria Announces Pricing of $1.6 Million Registered Direct Offering

Sep 21, 2023 9:10am EDT

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

Aug 30, 2023 9:20am EDT

Lexaria Provides Update on Investigational New Drug Application Progress

Aug 09, 2023 9:15am EDT

Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!

Aug 02, 2023 9:10am EDT

Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Jul 28, 2023 9:10am EDT

Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study

Jul 19, 2023 9:05am EDT

Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

Jun 22, 2023 9:25am EDT

Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science

Jun 20, 2023 9:05am EDT

Lexaria Receives New Patents

Jun 16, 2023 9:10am EDT

Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 22
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
2226 W. Northern Avenue
Phoenix, AZ 85021

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top